Literature DB >> 12365917

Expectations from clinical trials: results of the Early Manifest Glaucoma Trial.

Paul R Lichter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12365917     DOI： 10.1001/archopht.120.10.1371

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  5 in total

1.  Managing glaucoma in developing countries.

Authors:  Mauro Toledo Leite; Lisandro Massanori Sakata; Felipe Andrade Medeiros
Journal:  Arq Bras Oftalmol       Date:  2011 Mar-Apr       Impact factor: 0.872

2.  A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients.

Authors:  Gianluca Manni; Marco Centofanti; Mariacristina Parravano; Francesco Oddone; Massimo G Bucci
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

3.  Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial.

Authors:  Douglas G Day; Thomas R Walters; Gail F Schwartz; Thomas K Mundorf; Charlie Liu; Rhett M Schiffman; Marina Bejanian
Journal:  Br J Ophthalmol       Date:  2013-06-06       Impact factor: 4.638

4.  Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.

Authors:  Alfonso García-López; José A Paczka; Jesús Jiménez-Román; Curt Hartleben
Journal:  BMC Ophthalmol       Date:  2014-12-19       Impact factor: 2.209

5.  Brain MRI findings in infants with primary congenital glaucoma.

Authors:  Alper Ibrahým Dai; Oguzhan Saygili
Journal:  Ann Saudi Med       Date:  2007 Jul-Aug       Impact factor: 1.526
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.